Xilio Therapeutics

(NASDAQ) XLO

Current Price$9.18

Market Cap$62.99M

Since IPO (2021)-96%

5 YearN/A

1 Year+1%

1 Month+13%

Xilio Therapeutics Financials at a Glance

Market Cap

$62.99M

Revenue (TTM)

$53.48M

Net Income (TTM)

-$31.30M

EPS (TTM)

-$3.66

P/E Ratio

-2.62

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.18

Volume

441

Open

$9.57

Price

$9.18

Volume

441

Open

$9.57

Previous Close

$9.18

Daily Range

$9.18 - $9.57

52-Week Range

$6.47 - $12.74

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.18

Volume

441

Open

$9.57

Previous Close

$9.18

Daily Range

$9.18 - $9.57

52-Week Range

$6.47 - $12.74

Estimated Earnings Date

Aug 13, 2026

XLO News

Xilio Revenue Jumps 246 Percent in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xilio Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

René Russo, PharmD

Website

www.xiliotx.com

Headquarters

Waltham, MA 02451, US

XLO Financials

Key Financial Metrics (TTM)

Gross Margin

70.69%

Operating Margin

-78.98%

Net Income Margin

-58.52%

Return on Equity

-117.24%

Return on Capital

-99.42%

Return on Assets

-19.15%

Earnings Yield

-38.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$62.99M

Shares Outstanding

6.58M

Volume

441

Avg. Volume

44.74K

Financials (TTM)

Gross Profit

$37.81M

Operating Income

-$42.24M

EBITDA

-$29.91M

Operating Cash Flow

-$56.31M

Capital Expenditure

-$1.05M

Free Cash Flow

-$57.37M

Cash & ST Invst.

$150.33M

Total Debt

$6.64M

Xilio Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$12.65M

+331.7%

Gross Profit

$12.30M

+319.9%

Gross Margin

97.28%

N/A

Market Cap

$62.99M

N/A

Market Cap/Employee

$984.22K

N/A

Employees

N/A

Net Income

-$9.53M

+28.2%

EBITDA

-$9.19M

+28.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$150.33M

+68.8%

Total Debt

$6.64M

-15.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.25M

-20.8%

Short Term Debt

$1.38M

+12.9%

Return on Assets

-19.15%

N/A

Return on Invested Capital

-35.05%

N/A

Free Cash Flow

-$22.90M

-179.1%

Operating Cash Flow

-$22.34M

-177.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OKUROnKure Therapeutics, Inc.

OKUROnKure Therapeutics, Inc.$4.46-2.19%

KZRKezar Life Sciences, Inc.

KZRKezar Life Sciences, Inc.$7.29+0.00%

PDSBPDS Biotechnology Corporation

PDSBPDS Biotechnology Corporation$0.87-0.81%

LVTXLAVA Therapeutics N.V.

LVTXLAVA Therapeutics N.V.$1.74-3.87%

FGENFibroGen, Inc.

FGENFibroGen, Inc.$9.07-1.63%

ALGSAligos Therapeutics, Inc.

ALGSAligos Therapeutics, Inc.$5.45-5.55%

SKYESkye Bioscience, Inc.

SKYESkye Bioscience, Inc.$0.68-2.61%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$197.58-0.01%

TAT&T

TAT&T$20.48-0.01%

PATHUiPath

PATHUiPath$11.55+0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.46-0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.50+0.02%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.34+0.02%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.00+0.02%

Questions About XLO

What is the current price of Xilio Therapeutics?

Xilio Therapeutics is trading at $9.18 per share.

What is the 52-week range for Xilio Therapeutics?

Over the past 52 weeks, Xilio Therapeutics has traded between $6.47 and $12.74.

How much debt does Xilio Therapeutics have?

As of the most recent reporting period, Xilio Therapeutics reported total debt of $6.64M.

How much cash does Xilio Therapeutics have on hand?

Xilio Therapeutics reported $150.33M in cash and cash equivalents in its most recent financial results.

What is Xilio Therapeutics’s dividend yield?

Xilio Therapeutics does not currently have a dividend yield.

Xilio Therapeutics

Xilio Therapeutics Financials at a Glance

XLO News

Xilio Revenue Jumps 246 Percent in Q2

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Xilio Therapeutics

XLO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Xilio Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About XLO

What is the current price of Xilio Therapeutics?

What is the 52-week range for Xilio Therapeutics?

How much debt does Xilio Therapeutics have?

How much cash does Xilio Therapeutics have on hand?

What is Xilio Therapeutics’s dividend yield?

Premium Investing Services